related documents
- DETERMINANTS OF VIROLOGIC RELAPSE FOLLOWING HEPATITIS C ANTIVIRAL THERAPY: ANALYSIS OF THE CANADIAN POWER PROGRAM Conferences
- EXTENDED TREATMENT WITH PEGINTERFERON ALFA-2A BENEFITS PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B WITH A PARTIAL RESPONSE AFTER 48 WEEKS OF THERAPY - CLINICAL EXPERIENCE FROM A CHINESE CENTER Conferences
- OUTCOMES OF A LARGE, INCLUSIVE POPULATION-BASED HEPATITIS C TREATMENT PROGRAM ARE SIMILAR TO RANDOMIZED CONTROLLED TRIALS: INTERIM RESULTS OF THE CANADIAN REDIPEN PROGRAM Conferences
- PEGINTERFERON ALPHA-2A MAY ACHIEVE HIGHER SUSTAINED VIROLOGICAL RESPONSE THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: A COCHRANE SYSTEMATIC REVIEW OF RANDOMIZED CLINICAL TRIALS Conferences
- TRANSIENT ELASTOGRAPHY (FIBROSCAN) IN CHRONIC HEPATITIS B INFECTION: REDUCE NUMBER OF BIOPSIES & SAVE MONEY Conferences